Tesamorelin (5 mg Vial)

Tesamorelin Research Chart

Tesamorelin has been studied in scientific research for its biological activity and potential applications under controlled laboratory conditions. Research methods and study parameters vary depending on the objectives and experimental design. This content is provided for scientific and educational purposes only and does not include research, preparation, or administration guidance.

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH). It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research.

Educational guide for reconstitution and daily research

Standard FDA-Approved Protocol (2.5 mL = 2.0 mg/mL)

Week	Daily Blend (mg)	Volume (mL)
Week 1	1 mg / 1000 mcg	50 units (0.50 mL)
Weeks 2–12+	2 mg / 2000 mcg	100 units (1.00 mL)

Frequency: Research methodologies and study parameters vary depending on the objectives, laboratory conditions, and experimental design. This content is provided for scientific and educational purposes only and does not include administration, research, or treatment guidance.

Reconstitution Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Research timelines and study parameters vary depending on the objectives, laboratory methodology, and experimental design of each scientific investigation.

Concise summary of the FDA-approved once-daily regimen.

Goal: Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation.
Schedule: Study duration and research timelines may vary depending on the research design.
Research Range: 2 mg (2000 mcg) daily after Week 1 titration.
Reconstitution: 2.5 mL per 5 mg vial (2.0 mg/mL) for accurate measurement.
Storage: Lyophilized refrigerated; reconstituted refrigerated up to 7 days; avoid freeze-thaw.

Research methodology and study parameters vary depending on the objectives, laboratory conditions, and experimental design.

Week 1: 1 mg (1000 mcg) once daily to assess tolerability.
Research Phase: Research parameters and study methodologies vary depending on the objectives, experimental design, and controlled laboratory conditions.
Frequency: Once per day (subcutaneous), preferably in the evening.
Cycle Length: 12–26 weeks; clinical trials support up to 52 weeks with monitoring.
Timing: Timing and study conditions may vary depending on the research protocol.

Proper storage preserves peptide quality and efficacy.

Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution.
Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days.
Reconstituted (with sterile water): Use immediately; discard any unused portion.
Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container
Research procedures may vary depending on the study design and laboratory protocols.
Inject slowly; wait a few seconds before withdrawing the needle.
Monitor IGF-1 levels periodically due to potent GH stimulation; observe blood glucose in diabetic patients.
Document daily research and site rotation to maintain consistency.

Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines.

Observations from clinical trials and FDA-approved use.

Potential Benefits:

Significant reduction in visceral adipose tissue (measurable after 3–6 months).
Improved lipid profiles and potential liver fat reduction in NAFLD.
Enhanced cognitive function in older adults (research ongoing).
Well-tolerated with maintained benefits during continuous use up to 52 weeks.

Common Side Effects:

Research Observations: Research findings and laboratory observations may vary depending on the study design, methodology, and experimental conditions.
Musculoskeletal symptoms: Joint pain (arthralgia), muscle aches, peripheral edema (mild swelling).
Carpal tunnel saymptoms: Occasional tingling or numbness in extremities (research-dependent, reversible).
Metabolic monitoring: IGF-1 elevation requires monitoring; small increases in HbA1c observed in some patients.

Contraindications:

Complementary strategies for optimal outcomes.

Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects.
Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits.
Prioritize 7–9 hours of quality sleep to optimize natural GH pulsatility.
Manage stress through mindfulness or relaxation techniques to support adherence and recovery.

General subcutaneous guidance from clinical best‑practice resources.

Clean the vial stopper and skin with alcohol swabs; allow to air-dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue
Insert the needle at 90° (if adequate subcutaneous fat) or 45° (if lean)
Release the pinch, then inject slowly; wait 2–3 seconds before withdrawing.
Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
Dispose of used syringes immediately in a puncture-proof sharps container.

We recommend Vitality Labs Peptides for high-purity Tesamorelin (5 mg).

Why Research Information Matters?

This content is for educational purposes only and is not medical advice.

Explore related research protocols and background reading for BPC-157 + TB-500.

Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

— National Institutes of Health, NIDDK (2018)

Tesamorelin (Subcutaneous route) – Drug Information

— Mayo Clinic / IBM Merative (2025)

Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials

— J. Clin. Endocrinol. Metab. (2010)

Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trial

— PLoS ONE (2017)

Tesamorelin can improve cognitive function (Research Highlight)

— Nature Reviews Endocrinology (2012)

Tesamorelin Research Information – Scientific References

— MedlinePlus (U.S. National Library of Medicine) (2025)

EGRIFTA SV (tesamorelin) – Full Prescribing Information

— Theratechnologies, Inc. (FDA Label) (2024)

Tesamorelin: Scientific Research Overview

— Drugs.com (AHFS Monograph & Patient Info) (2025)

Tesamorelin – LiverTox (Safety Profile)

— NIH NIDDK LiverTox Database (2018)

Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)

— Open RN, Chippewa Valley Technical College (2023)

Tesamorelin 5 mg Research Information

— Quality and batch documentation for research-grade tesamorelin